Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1 4Phase 1/2 2Phase NA 1Phase 4 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Plasma cell 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 255Breast Neoplasms 171Neoplasms 166Colorectal Neoplasms 152Neoplasm Metastasis 125Prostatic Neoplasms 118Recurrence 117Leukemia, Myeloid, Acute 117Melanoma 116Pancreatic Neoplasms 114Ovarian Neoplasms 109Multiple Myeloma 105Lung Neoplasms 94Stomach Neoplasms 92Triple Negative Breast Neoplasms 86Squamous Cell Carcinoma of Head and Neck 86Lymphoma 77Glioblastoma 77Lymphoma, Non-Hodgkin 76Lymphoma, Large B-Cell, Diffuse 65Carcinoma, Renal Cell 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 63Carcinoma, Hepatocellular 58Endometrial Neoplasms 56Advanced Solid Tumor 56Small Cell Lung Carcinoma 55Uterine Cervical Neoplasms 53Sarcoma 53Myelodysplastic Syndromes 51Leukemia 50

Interventions

selinexor 1pazopanib 1Proton Therapy 1Ifosfamide 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Hemangiosarcoma × 1 year × Clear all
NCT06239272 2026-05-19

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
139 enrolled
Plasma cellSarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

NCT05826600 2026-04-24

A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically

iOmx Therapeutics AG

Phase 1/2 Terminated
68 enrolled
GenitourinarySarcoma

Carcinoma, Renal Cell, Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡